MwanzoMVIR • STO
add
Medivir AB
Bei iliyotangulia
kr 2.70
Bei za siku
kr 2.66 - kr 2.74
Bei za mwaka
kr 2.33 - kr 4.71
Thamani ya kampuni katika soko
303.97M SEK
Wastani wa hisa zilizouzwa
elfu 89.72
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
STO
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (SEK) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | elfu 900.00 | 12.50% |
Matumizi ya uendeshaji wa biashara | 7.30M | 5.80% |
Mapato halisi | -34.60M | -46.61% |
Kiwango cha faida halisi | elfu -3.84 | -30.32% |
Mapato kwa kila hisa | -0.30 | 28.57% |
EBITDA | -35.30M | -50.21% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (SEK) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 92.50M | 51.39% |
Jumla ya mali | 204.20M | 15.96% |
Jumla ya dhima | 62.40M | 20.93% |
Jumla ya hisa | 141.80M | — |
hisa zilizosalia | 112.17M | — |
Uwiano wa bei na thamani | 2.14 | — |
Faida inayotokana na mali | -40.60% | — |
Faida inayotokana mtaji | -53.35% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (SEK) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -34.60M | -46.61% |
Pesa kutokana na shughuli | -33.40M | -59.05% |
Pesa kutokana na uwekezaji | — | — |
Pesa kutokana na ufadhili | elfu -600.00 | 0.00% |
Mabadiliko halisi ya pesa taslimu | -34.10M | -57.14% |
Mtiririko huru wa pesa | -21.80M | -71.32% |
Kuhusu
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1988
Tovuti
Wafanyakazi
10
